Dataset Information

The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results.

ABSTRACT: Cerebral ischemia and reperfusion initiate cellular events in brain that lead to neurological disability. Investigating these cellular events provides ample targets for developing new treatments. Despite considerable work, no such therapy has translated into successful stroke treatment. Among other issues-such as incomplete mechanistic knowledge and faulty clinical trial design-a key contributor to prior translational failures may be insufficient scientific rigor during preclinical assessment: nonblinded outcome assessment; missing randomization; inappropriate sample sizes; and preclinical assessments in young male animals that ignore relevant biological variables, such as age, sex, and relevant comorbid diseases. Promising results are rarely replicated in multiple laboratories. We sought to address some of these issues with rigorous assessment of candidate treatments across 6 independent research laboratories. The Stroke Preclinical Assessment Network (SPAN) implements state-of-the-art experimental design to test the hypothesis that rigorous preclinical assessment can successfully reduce or eliminate common sources of bias in choosing treatments for evaluation in clinical studies. SPAN is a randomized, placebo-controlled, blinded, multilaboratory trial using a multi-arm multi-stage protocol to select one or more putative stroke treatments with an implied high likelihood of success in human clinical stroke trials. The first stage of SPAN implemented procedural standardization and experimental rigor. All participating research laboratories performed middle cerebral artery occlusion surgery adhering to a common protocol and rapidly enrolled 913 mice in the first of 4 planned stages with excellent protocol adherence, remarkable data completion and low rates of subject loss. SPAN stage 1 successfully implemented treatment masking, randomization, prerandomization inclusion/exclusion criteria, and blinded assessment to exclude bias. Our data suggest that a large, multilaboratory, preclinical assessment effort to reduce known sources of bias is feasible and practical. Subsequent SPAN stages will evaluate candidate treatments for potential success in future stroke clinical trials using aged animals and animals with comorbid conditions.

SUBMITTER: Lyden PD

PROVIDER: S-EPMC9038686 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results.

Lyden Patrick D PD Bosetti Francesca F Diniz Márcio A MA Rogatko André A Koenig James I JI Lamb Jessica J Nagarkatti Karisma A KA Cabeen Ryan P RP Hess David C DC Kamat Pradip K PK Khan Mohammad B MB Wood Kristofer K Dhandapani Krishnan K Arbab Ali S AS Leira Enrique C EC Chauhan Anil K AK Dhanesha Nirav N Patel Rakesh B RB Kumskova Mariia M Thedens Daniel D Morais Andreia A Imai Takahiko T Qin Tao T Ayata Cenk C Boisserand Ligia S B LSB Herman Alison L AL Beatty Hannah E HE Velazquez Sofia E SE Diaz-Perez Sebastian S Sanganahalli Basavaraju G BG Mihailovic Jelena M JM Hyder Fahmeed F Sansing Lauren H LH Koehler Raymond C RC Lannon Steven S Shi Yanrong Y Karuppagounder Senthilkumar S SS Bibic Adnan A Akhter Kazi K Aronowski Jaroslaw J McCullough Louise D LD Chauhan Anjali A Goh Andrew A

Stroke 20220331 5

Cerebral ischemia and reperfusion initiate cellular events in brain that lead to neurological disability. Investigating these cellular events provides ample targets for developing new treatments. Despite considerable work, no such therapy has translated into successful stroke treatment. Among other issues-such as incomplete mechanistic knowledge and faulty clinical trial design-a key contributor to prior translational failures may be insufficient scientific rigor during preclinical assessment: n ...[more]

PMID: 35354299

Similar Datasets

Project description:The Stroke Preclinical Assessment Network (SPAN) is a multicenter preclinical trial platform using rodent models of transient focal cerebral ischemia to address translational failure in experimental stroke. In addition to centralized randomization and blinding and large samples, SPAN aimed to introduce heterogeneity to simulate the heterogeneity embodied in clinical trials for robust conclusions. Here, we report the heterogeneity introduced by allowing the 6 SPAN laboratories to vary most of the biological and experimental model variables and the impact of this heterogeneity on middle cerebral artery occlusion (MCAo) performance. We included the modified intention-to-treat population of the control mouse cohort of the first SPAN trial (n=421) and examined the biological and procedural independent variables and their covariance. We then determined their impact on the dependent variables cerebral blood flow drop during MCAo, time to achieve MCAo, and total anesthesia duration using multivariable analyses. We found heterogeneity in biological and procedural independent variables introduced mainly by the site. Consequently, all dependent variables also showed heterogeneity among the sites. Multivariable analyses with the site as a random effect variable revealed filament choice as an independent predictor of cerebral blood flow drop after MCAo. Comorbidity, sex, use of laser Doppler flow to monitor cerebral blood flow, days after trial onset, and maintaining anesthesia throughout the MCAo emerged as independent predictors of time to MCAo. Total anesthesia duration was predicted by most independent variables. We present with high granularity the heterogeneity introduced by the biological and model selections by the testing sites in the first trial of cerebroprotection in rodent transient filament MCAo by SPAN. Rather than trying to homogenize all variables across all sites, we embraced the heterogeneity to better approximate clinical trials. Awareness of the heterogeneity, its sources, and how it impacts the study performance may further improve the study design and statistical modeling for future multicenter preclinical trials.

Dataset Information

The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results.

Publications

The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets